KHK2823
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Trial Timeline
Jun 1, 2014 → May 10, 2019
NCT ID
NCT02181699About KHK2823
KHK2823 is a phase 1 stage product being developed by Kyowa Kirin for Acute Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02181699. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02181699 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia